Spyre Therapeutics, Inc. financial data

Symbol
SYRE on Nasdaq
Industry
Pharmaceutical Preparations
Location
221 Crescent Street, Building 23, Suite 105, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Aeglea BioTherapeutics, Inc. (to 11/24/2023)
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.04K % +571%
Debt-to-equity 60.7 %
Return On Equity -160 % -108%
Return On Assets -50.5 % +78.7%
Operating Margin -39.4K % -480%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.8M shares -49.8%
Common Stock, Shares, Outstanding 50.8M shares -37.3%
Entity Public Float 26.2M USD -13.5%
Common Stock, Value, Issued 12K USD +100%
Weighted Average Number of Shares Outstanding, Basic 45.3M shares +1085%
Weighted Average Number of Shares Outstanding, Diluted 45.3M shares +1085%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 55.4M USD -11%
General and Administrative Expense 47M USD +60.3%
Operating Income (Loss) -156M USD +27.7%
Nonoperating Income (Expense) -29.8M USD +47.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -186M USD +31.8%
Income Tax Expense (Benefit) 35K USD -100%
Net Income (Loss) Attributable to Parent -186M USD +31.8%
Earnings Per Share, Basic 10.5 USD/shares +98.5%
Earnings Per Share, Diluted 10.5 USD/shares +98.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 45.1M USD -80.8%
Cash, Cash Equivalents, and Short-term Investments 426M USD
Assets, Current 436M USD +81.6%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 10K USD 0%
Assets 436M USD +79.1%
Accounts Payable, Current 2.85M USD +45.8%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 22.1M USD -90.5%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 61.7M USD -75.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -553K USD -5127%
Retained Earnings (Accumulated Deficit) -847M USD -28.1%
Stockholders' Equity Attributable to Parent 374M USD
Liabilities and Equity 436M USD +79.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.5M USD -61.9%
Net Cash Provided by (Used in) Financing Activities 172M USD
Net Cash Provided by (Used in) Investing Activities -105M USD -691%
Common Stock, Shares Authorized 400M shares -20%
Common Stock, Shares, Issued 50.8M shares -37.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 38.7M USD +28116%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 45.5M USD -80.8%
Deferred Tax Assets, Valuation Allowance 125M USD +16.6%
Deferred Tax Assets, Gross 125M USD +15.8%
Operating Lease, Liability 4.63M USD -8.23%
Payments to Acquire Property, Plant, and Equipment 37K USD -91.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -187M USD +31.5%
Lessee, Operating Lease, Liability, to be Paid 6.07M USD -13.3%
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.1M USD +3.67%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.08M USD +13.7%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -104%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.45M USD -26.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.13M USD +3.01%
Deferred Tax Assets, Operating Loss Carryforwards 74.5M USD +8.03%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 8.64M shares -13.6%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.16M USD +3.01%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 0 USD -100%
Share-based Payment Arrangement, Expense 8.68M USD +354%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%